Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease

Movement Disorders

Volumn 29, Issue 8, 2014, Pages 999-1009

  Kelly, Leo P ^a   Carvey, Paul M ^a   Keshavarzian, Ali ^a,b,c   Shannon, Kathleen M ^b   Shaikh, Maliha ^b   Bakay, Roy A E ^a   Kordower, Jeffrey H ^b  

^a RUSH UNIVERSITY   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Animal model; Enteric nervous system; Parkinson; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; GASTROINTESTINAL AGENT; POLYSACCHARIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL; BRAIN; C57BL MOUSE; COLON; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; GAS CHROMATOGRAPHY; MALE; METABOLISM; MOUSE; PARKINSON DISEASE; PATHOLOGY; PERMEABILITY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; URINE; VAGUS NERVE;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; CHROMATOGRAPHY, GAS; COLON; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GASTROINTESTINAL AGENTS; LINEAR MODELS; MALE; MICE; MICE, INBRED C57BL; PARKINSON DISEASE; PERMEABILITY; POLYSACCHARIDES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; VAGUS NERVE;

EID: 84904428155     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25736     Document Type: Article

References (61)

1. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinson disorders. Mov Disord 2003;18:467-486.
2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:2045-2047.
3. Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005;2:484-494.
4. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003;2:107-116.
5. White L, Petrovitch H, Ross GW, et al. Prevalence of dementia in older Japanese-American men in Hawaii: the Honolulu-Asia Aging Study. JAMA 1996;276:955-960.
6. Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR. Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord 2012;18(suppl 1):S199-S202.
7. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396:67-72.
8. Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 2012;27:716-719.
9. Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2012;27:709-715.
10. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 1988;76:217-221.
11. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990;79:581-583.
12. Takeda S, Yamazaki K, Miyakawa T, Arai H. Parkinson's disease with involvement of the parasympathetic ganglia. Acta Neuropathol 1993;86:397-398.
13. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997;38(suppl 2):2-7.
14. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689-702.
15. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
16. Drolet RE, Cannon JR, Montero L, Greenamyre JT. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis 2009;36:96-102.
17. Tasselli M, Chaumette T, Paillusson S, et al. Effects of oral administration of rotenone on gastrointestinal functions in mice [serial online]. Neurogastroenterol Motil 2013;25:e183-e193.
18. Pan-Montojo FJ, Schwarz M, Winkler C, et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice [serial online]. Sci Rep. 2012;2:898.
19. Wang L, Magen I, Yuan PQ, Subramaniam SR, Richter F, Chesselet MF, Tache Y. Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation [serial online]. Neurogastroenterol Motil 2012;24:e425-e436.
20. Noorian AR, Rha J, Annerino DM, Bernhard D, Taylor GM, Greene JG. Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system. Neurobiol Dis 2012;48:9-19.
21. Hallett PJ, McLean JR, Kartunen A, Langston JW, Isacson O. Alpha-synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis 2012;47:258-267.
22. Lee HJ, Suk JE, Lee KW, Park SH, Blumbergs PC, Gai P, Lee SP. Transmission of synucleinopathies in the enteric nervous system of A53T alpha-synuclein transgenic mice. Exp Neurobiol 2011;20:181-188.
23. Pan-Montojo F, Anichtchik O, Dening Y. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice [serial online]. PLoS One 2010;5:e8762.
24. Kuo YM, Li Z, Jiao Y, et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 2010;19:1633-1650.
25. Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? Neuroscience 2008;153:733-750.
26. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease [serial online]. PLOS One. 2011;6:e28032.
27. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995;108:1566-1581.
28. Keita AV, Soderholm JD. The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenterol Motil 2010;22:718-733.
29. Lema Tome CM, Tyson T, Rey NL, Grathwol S, Britschqi M, Brudin P. Inflammation and alpha-synuclein's prion-like behavior in Parkinson's disease-is there a link? Mol Neurobiol 2012;47:561-574.
30. Farhadi A, Banan A, Fields J, Keshavarzian A. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol 2003;18:479-497.
31. Qin L, Wu X, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007;55:453-462.
32. Liu Y, Qin L, Wilson B, Wu X, Qian L, Granholm AC, Crews FT, Hong JS. Endotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits. Neurotoxicology. 2008;29:864-870.
33. Chu Y, Kordower JH. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol Disease 2007;25;134-149.
34. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, Keshavarzian A. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 2009;43:163-172.
35. Keshavarzian A, Farhadi A, Forsyth CB, et al. Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol 2009;50:538-547.
36. Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, Keshavarian A. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008;28:1026-1033.
37. Farhadi A, Keshavarzian A, Fields JZ, Sheikh M, Banan A. Resolution of common dietary sugars from probe sugars for test of intestinal permeability using capillary column gas chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2006;836:63-68.
38. Ma SY, Ciliax BJ, Stebbins G, et al. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol 1999;409:25-37.
39. Castano A, Herrera AJ, Cano J, Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 1998;70:1584-1592.
40. Bing G, Lu X, Zheng NA, Jin L, Qi Y, Kim H-C. Microglia mediated dopaminergic cell death in the substantia nigra: a new animal model for Parkinson's disease [abstract]. Neurosci Abstracts 1998;24:44.
41. Herrera AJ, Castano A, Venero JL, Cano J, Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 2000;7:429-447.
42. Zhang J, Stanton DM, Nguyen XV, Liu M, Zhang Z, Gash D, Bing G. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits. Neuroscience 2005;135:829-838.
43. Choi DY, Liu M, Hunter RL, et al. Striatal neuroinflammation promotes parkinsonism in rats [serial online]. PLoS One 2009;4:e5482.
44. Gill SR, Pop M, DeBoy RT, et al. Metagenomic analysis of the human distal gut micobiome. Science 2006;312:1355-1359.
45. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010;119:703-713.
46. Bloch A, Probst A, Bissig H, Adams H, Tolnay M. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subject. Neuropathol Appl Neurobiol 2006;32:284-295.
47. Bottner M, Zorenkov D, Hellwig I, et al. Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol Dis 2012;48:474-480.
48. Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987;37:1253-1255.
49. Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's. Gastroenterology 1984;87:848-856.
50. Devos D, Lebouvier T, Lardeux B, et al. Colonic inflammation in Parkinson's disease. Neurobiol Dis 2013;50:42-48.
51. Cersosimo MG, Raina GB, Pecci C, et al. Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. J Neurol. 2013;260:1332-1338.
52. Annerino DM, Arshad S, Taylor GM, Alder CH, Beach TG, Greene JG. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol 2012;124:665-680.
53. Pouclet H, Lebouvier T, Coron E, et al. A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease. Neurobiol Dis 2012;45:305-309.
54. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms[serial online]. PLOS One. 2010;5:e12728.
55. Lebouvier T, Chaumette T, Damier P, et al. Pathological lesions in colonic biopsies during Parkinson's disease. Gut. 2008;57:1741-1743.
56. Berthoud HR, Carlson NR, Powley TL. Topography of efferent vagal innervation of the rat gastrointestinal tract. Am J Physiol 1991;260:200-207.
57. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456-462.
58. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007;22:1581-1586.
59. Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009;73:1752-1758.
60. Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of Parkinson's disease. Am J Epidemiol 2011;174:546-551.
61. Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR. Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord 2012;18(suppl 1):S199-S202.